Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Internal Medicine | Oncology | Journal

Back to Journal Articles

New Transplant Platform Successful in Sickle Cell

Last Updated: September 27, 2012.

 

Non-myeloablative bone marrow transplantation platform may expand donor eligibility

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Non-myeloablative conditioning with post-transplantation high-dose cyclophosphamide expands the donor pool for bone marrow transplantation for patients with sickle cell disease, according to a preliminary study published online Sept. 6 in Blood.

THURSDAY, Sept. 27 (HealthDay News) -- Non-myeloablative conditioning with post-transplantation high-dose cyclophosphamide expands the donor pool for bone marrow transplantation for patients with sickle cell disease, according to a preliminary study published online Sept. 6 in Blood.

Javier Bolaños-Meade, M.D., from Johns Hopkins University in Baltimore, and colleagues developed a non-myeloablative bone marrow transplantation platform using related, including HLA-haploidentical, donors for patients with sickle cell disease.

The researchers performed a transplant in 17 sickle cell patients: 14 from HLA-haploidentical and three from HLA-matched related donors. Eleven patients engrafted durably. At a median follow-up of 711 days (minimal follow-up, 224 days), 10 patients were asymptomatic and six patients were off immunosupression. Skin-only acute graft-versus-host disease occurred in one patient and resolved without any therapy. No mortality was observed.

"Non-myeloablative conditioning with post-transplantation high-dose cyclophosphamide expands the donor pool making marrow transplantation feasible for most patients with sickle cell disease and is associated with a low risk of complications, even with haploidentical related donors," the authors write.

Several authors are listed as inventors on a patent application related to the study subject matter; one author disclosed financial ties to HemaQuest Pharmaceuticals.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Much of Intellectual Disability Not Genetically Inherited Next: Study Supports Diet High in Total Antioxidants for Lower MI Risk

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.